But this also creates a paradox: some companies or providers may see reduced volumes or sales of these high-cost services, posing challenges to traditional healthcare business modelssomething management teams and healthcare investors are watching very closely
Citing limitations in the study, Novo Nordisk, which makes the drugs included in the claims analysis, said in a statement reported by Reuters that it does not believe these data are sufficient to draw conclusions about overall patient adherence and persistence to various GLP-1 medicines, including our treatments. Nonetheless, the problem of lack of patient persistence on GLP-1s under real-world conditions, examined and published by a growing number of sources, isnt going away
Nevertheless, aim for 8-10 cups (64-80 ounces) of water daily
Cardiovascular outcomes trials have demonstrated significant benefits of certain GLP-1 agonists beyond glycemic control
These side effects are often mild and tend to improve over time
These drugs are just too large to slip through the skin